Javascript must be enabled to continue!
Partners in Claim: Litigation Funding as Quasi-Partnerships
View through CrossRef
<div>
<p>The third-party litigation funding (TPLF) industry is a rapidly growing phenomenon in the U.S., making headlines in cases ranging from celebrity privacy scandals to multimillion-dollar NFL head injury lawsuits. Proponents praise TPLF for increasing access to justice, particularly for underprivileged parties who may otherwise lack the resources to pursue their claims. Critics, however, warn that it fosters opacity, promotes frivolous lawsuits, inflates legal costs, and allows funders to exert undue influence over litigation strategies and settlement negotiations. To address these commonly held criticisms while preserving the advantages of the practice, this Article proposes a novel approach to TPLF, reconceptualizing these arrangements as a quasi-partnership. Based on the regulatory and theoretical principles governing limited partnerships, we develop a framework that specifies the roles, rights, and duties of claimants, funders, and their attorneys. The funders serve as “limited partners,” providing capital but being barred from directing litigation strategy or settlement decisions. Claimants are cast as “general partners,” retaining substantive control but bound by fiduciary duties to the “partnership,” including the funder’s interests. The claimant’s attorney, in turn, is redefined as owing duties to both the client and the partnership as a whole, balancing the interests of all parties involved. This framework clarifies why funders should have limited control over litigation decisions, delineates necessary disclosure obligations, and defines the permissible scope of funder access to case-related information. The proposed model is not only a more accurate account of how TPLF operates in practice but is also normatively superior to current arrangements, offering a principled and economically efficient model for integrating TPLF into modern litigation practices—one that preserves its access-to-justice benefits and mitigates its potential risks.<i></i></p>
</div>
Title: Partners in Claim: Litigation Funding as Quasi-Partnerships
Description:
<div>
<p>The third-party litigation funding (TPLF) industry is a rapidly growing phenomenon in the U.
S.
, making headlines in cases ranging from celebrity privacy scandals to multimillion-dollar NFL head injury lawsuits.
Proponents praise TPLF for increasing access to justice, particularly for underprivileged parties who may otherwise lack the resources to pursue their claims.
Critics, however, warn that it fosters opacity, promotes frivolous lawsuits, inflates legal costs, and allows funders to exert undue influence over litigation strategies and settlement negotiations.
To address these commonly held criticisms while preserving the advantages of the practice, this Article proposes a novel approach to TPLF, reconceptualizing these arrangements as a quasi-partnership.
Based on the regulatory and theoretical principles governing limited partnerships, we develop a framework that specifies the roles, rights, and duties of claimants, funders, and their attorneys.
The funders serve as “limited partners,” providing capital but being barred from directing litigation strategy or settlement decisions.
Claimants are cast as “general partners,” retaining substantive control but bound by fiduciary duties to the “partnership,” including the funder’s interests.
The claimant’s attorney, in turn, is redefined as owing duties to both the client and the partnership as a whole, balancing the interests of all parties involved.
This framework clarifies why funders should have limited control over litigation decisions, delineates necessary disclosure obligations, and defines the permissible scope of funder access to case-related information.
The proposed model is not only a more accurate account of how TPLF operates in practice but is also normatively superior to current arrangements, offering a principled and economically efficient model for integrating TPLF into modern litigation practices—one that preserves its access-to-justice benefits and mitigates its potential risks.
<i></i></p>
</div>.
Related Results
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). Several studie...
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Background: Lytic bone lesions are one of the most common clinical characteristics of patients with multiple myeloma (MM) and identification of bone lesions help distinguish betwee...
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
BACKGROUND
Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma in which bone marrow is infiltrated by immunoglobulin M (IgM)-producing clonal lymphopl...
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Abstract
BACKGROUND: Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) entails sudden life changes including acute symptom burden, changes in phy...
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Abstract
Background:
GLUT4 inhibition is an attractive therapeutic option in multiple myeloma (MM) given the dependence of MM cells on glucose transpo...
Measuring the Value of Litigation Finance
Measuring the Value of Litigation Finance
<p><span>Litigation finance has become a focal point of contemporary debates about civil justice yet those debates remain largely theoretical and rest on untested empir...
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Abstract
Abstract 3424
Patients with aplastic anemia (AA) are suffered from various complications related to bone marrow failure and peripheral cytope...
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Abstract
Background
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for acute myeloid leukemia (AML),...

